17 August 2018 - The PBAC minutes pertaining to the draft review report for the post-market review of the use of biologics in the treatment of severe chronic plaque psoriasis are now available.

The review was recommended by the PBAC at its December 2015 meeting and approved by the Minister for Health on 7 April 2016.

The draft report, including PBAC sub-committee advice and stakeholder comments, was provided to the PBAC for consideration in April 2018.

Considering the findings from Terms of Reference 1, 2 and 3, the PBAC recommended a review of the cost-effectiveness of biologics for severe chronic plaque psoriasis under Term of Reference 4. The cost-effectiveness review will be addressed in the final review report.

Read minutes of draft review report